Group 1 - The company, Hansai Aitai-B (03378), plans to conduct a global offering of 18.321 million shares from December 15 to December 18, 2025, with 10% allocated for Hong Kong and 90% for international sales, at a price range of HKD 28-32 per share [1] - The company specializes in structural biology, translational medicine, and clinical development, with a product pipeline that includes one core product and nine other candidates, focusing on oncology and autoimmune markets [1] - The company has developed three clinical-stage candidates for oncology, including its core product HX009 and major products HX301 and HX044, along with seven preclinical candidates [1] Group 2 - The company estimates a net amount of approximately HKD 496 million from the global offering at a median indicative price of HKD 30.00 per share, after deducting underwriting commissions and expenses [2] - The intended use of the net proceeds includes approximately 35% for the development of the core product HX009, 33% for major products HX301 and HX044, 17% for other important product development, 5% for commercialization and business development, and 10% for working capital and general corporate purposes [2]
翰思艾泰-B于12月15日至12月18日招股 预计12月23日上市
Xin Lang Cai Jing·2025-12-15 00:28